Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type September 2020 ESMO 2020 Read more
2023 February Cancer trials Futibatinib demonstrates clinical benefit in FGFR2-rearranged intrahepatic cholangiocarcinoma Read more
2023 January Medical Research Interactions between eosinophils and T cells are crucial in response to Immunotherapy Read more
2023 January Clinical Practice Female cancer survivors experience a faster decline in physical functions Read more
2023 January Cancer trials Tovorafenib exhibits positive response in pediatric patients with glioma Read more
